Perioperative Lymphopenia is Associated with Increased Risk of Recurrence and Worse Survival Following Hepatectomy for Hepatocellular Carcinoma.
HCC
Lymphopenia
Resection
Surgery
Survival
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
05 Jan 2024
05 Jan 2024
Historique:
received:
11
10
2023
accepted:
07
12
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
5
1
2024
Statut:
aheadofprint
Résumé
Immune dysregulation may be associated with cancer progression. We sought to investigate the prognostic value of perioperative lymphopenia on short- and long-term outcomes among patients undergoing resection of hepatocellular carcinoma (HCC). Patients undergoing resection of HCC between 2000 and 2020 were identified using an international database. The incidence and impact of perioperative lymphopenia [preoperative, postoperative day (POD) 1/3/5], defined as absolute lymphocyte count (ALC) <1000/μL, on short- and long-term outcomes was assessed. Among 1448 patients, median preoperative ALC was 1593/μL [interquartile range (IQR) 1208-2006]. The incidence of preoperative lymphopenia was 14.0%, and 50.2%, 45.1% and 35.6% on POD1, POD3 and POD5, respectively. Preoperative lymphopenia predicted 5-year overall survival (OS) [lymphopenia vs. no lymphopenia: 49.1% vs. 66.1%] and 5-year disease-free survival (DFS) [25.0% vs. 41.5%] (both p < 0.05). Lymphopenia on POD1 (5-year OS: 57.1% vs. 71.2%; 5-year DFS: 30.0% vs. 41.1%), POD3 (5-year OS: 57.3% vs. 68.9%; 5-year DFS: 35.4% vs. 42.7%), and POD5 (5-year OS: 53.1% vs. 66.1%; 5-year DFS: 32.8% vs. 42.3%) was associated with worse long-term outcomes (all p < 0.05). Patients with severe lymphopenia (ALC <500/μL) on POD5 had worse 5-year OS and DFS (5-year OS: 44.7% vs. 54.3% vs. 66.1%; 5-year DFS: 27.8% vs. 33.3% vs. 42.3%) [both p < 0.05], as well as higher incidence of overall (45.5% vs. 25.3% vs. 30.9%; p = 0.013) and major complications (18.2% vs. 3.4% vs. 4.5%; p < 0.001) versus individuals with moderate (ALC 500-1000/μL) or no lymphopenia following hepatectomy for HCC. After adjusting for competing risk factors, prolonged lymphopenia was independently associated with higher hazards of death [hazard ratio (HR) 1.38, 95% CI 1.11-1.72] and recurrence (HR 1.22, 95% CI 1.02-1.45). Perioperative lymphopenia had short- and long-term prognostic implications among individuals undergoing hepatectomy for HCC.
Identifiants
pubmed: 38180707
doi: 10.1245/s10434-023-14811-7
pii: 10.1245/s10434-023-14811-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–49.
doi: 10.1016/j.jhep.2017.09.016
pubmed: 28989095
Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States Forecast Through 2030. J Clin Oncol. 2016;34(15):1787–94.
doi: 10.1200/JCO.2015.64.7412
pubmed: 27044939
pmcid: 4966339
Tsilimigras DI, Bagante F, Moris D, et al. Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: a multi-institutional analysis of 1010 patients. Surgery. 2019;166(6):967–74.
doi: 10.1016/j.surg.2019.08.010
pubmed: 31606196
Pinna AD, Yang T, Mazzaferro V, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg. 2018;268(5):868–75.
doi: 10.1097/SLA.0000000000002889
pubmed: 30080736
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.
doi: 10.1038/s41572-020-00240-3
pubmed: 33479224
Tsilimigras DI, Bagante F, Moris D, et al. Recurrence patterns and outcomes after resection of hepatocellular carcinoma within and beyond the Barcelona clinic liver cancer criteria. Ann Surg Oncol. 2020;27(7):2321–31.
doi: 10.1245/s10434-020-08452-3
pubmed: 32285278
Tsilimigras DI, Ntanasis-Stathopoulos I, Moris D, Pawlik TM. Liver tumor microenvironment. Adv Exp Med Biol. 2020;1296:227–41.
doi: 10.1007/978-3-030-59038-3_14
pubmed: 34185296
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.
doi: 10.1038/nature07205
pubmed: 18650914
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
doi: 10.1016/j.cell.2011.02.013
pubmed: 21376230
Ceze N, Thibault G, Goujon G, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 2011;68(5):1305–13.
doi: 10.1007/s00280-011-1610-3
pubmed: 21448592
De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012;12(4):264–9.
doi: 10.1016/j.clbc.2012.04.004
pubmed: 22591634
Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–91.
doi: 10.1158/0008-5472.CAN-08-3845
pubmed: 19549917
pmcid: 2775079
Aizawa M, Yabusaki H, Matsuki A, Bamba T, Nakagawa S. Predictive significance of surgery-induced lymphopenia on the survival after curative resection for locally advanced gastric cancer: a retrospective cohort analysis. World J Surg Oncol. 2023;21(1):7.
doi: 10.1186/s12957-023-02887-0
pubmed: 36647123
pmcid: 9841676
Cohen JT, Charpentier KP, Miner TJ, Cioffi WG, Beard RE. Lymphopenia following pancreaticoduodenectomy is associated with pancreatic fistula formation. Ann Hepatobiliary Pancreat Surg. 2021;25(2):242–50.
doi: 10.14701/ahbps.2021.25.2.242
pubmed: 34053927
pmcid: 8180408
Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010;21(1):3–10.
doi: 10.1016/j.cytogfr.2009.11.002
pubmed: 20005150
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48.
doi: 10.1016/j.immuni.2004.07.017
pubmed: 15308095
Alwarawrah Y, Kiernan K, MacIver NJ. Changes in nutritional status impact immune cell metabolism and function. Front Immunol. 2018;9:1055.
doi: 10.3389/fimmu.2018.01055
pubmed: 29868016
pmcid: 5968375
Hogan BV, Peter MB, Shenoy HG, Horgan K, Hughes TA. Surgery induced immunosuppression. Surgeon. 2011;9(1):38–43.
doi: 10.1016/j.surge.2010.07.011
pubmed: 21195330
Chiarelli M, Achilli P, Tagliabue F, et al. Perioperative lymphocytopenia predicts mortality and severe complications after intestinal surgery. Ann Transl Med. 2019;7(14):311.
doi: 10.21037/atm.2019.06.46
pubmed: 31475181
pmcid: 6694229
Toft P, Tonnesen E, Helbo-Hansen HS, Lillevang ST, Rasmussen JW, Christensen NJ. Redistribution of granulocytes in patients after major surgical stress. APMIS. 1994;102(1):43–8.
doi: 10.1111/j.1699-0463.1994.tb04843.x
pubmed: 8166999
Zidar DA, Al-Kindi SG, Liu Y, et al. Association of lymphopenia with risk of mortality among adults in the US general population. JAMA Netw Open. 2019;2(12):e1916526.
doi: 10.1001/jamanetworkopen.2019.16526
pubmed: 31790569
pmcid: 6902755
Romo EM, Munoz-Robles JA, Castillo-Rama M, et al. Peripheral blood lymphocyte populations in end-stage liver diseases. J Clin Gastroenterol. 2007;41(7):713–21.
doi: 10.1097/01.mcg.0000248000.42581.35
pubmed: 17667057